The Indian Pharmaceutical Market (IPM) reported a 10.5% growth in the January-March quarter of FY26, the highest in five quarters, according to market research firm Pharmarack. This growth was primarily driven by steady pricing, which remained around 5.4-5.5%, and a recovery in volume, which rose to 1.7% after several quarters of stagnation. Monthly data showed consistent growth, with January starting at 10.2%, peaking at 11% in February, and slightly moderating to 10.1% in March. Chronic therapies, particularly cardiac and anti-diabetic treatments, led the growth, with cardiac therapies showing 14.7% growth in March. The market is shifting towards chronic and sub-chronic therapies, which now account for 56% of the market, reflecting a transition from acute therapies, which have declined to 44%. This trend indicates a growing demand for lifestyle-related treatments, with chronic therapies expanding at a 12% compound annual growth rate, compared to 6% for acute therapies. The overall growth underscores the increasing importance of value-driven healthcare in India.